


The Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Original) A compound of the formula I:



(I)

or pharmaceutically acceptable salts thereof, wherein

Z is hydrogen, (C₃-C₇ cycloalkyl)₀₋₁(C₁-C₆ alkyl)-, (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkenyl)-, alkoxyalkoxyalkyl, (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkynyl)- or (C₃-C₇ cycloalkyl)-, wherein each of said groups is optionally substituted with 1, 2, or 3 R_Z groups, wherein 1 or 2 methylene groups within said (C₃-C₇ cycloalkyl)₀₋₁(C₁-C₆ alkyl)-, (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkenyl)-, (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkynyl)- or (C₃-C₇ cycloalkyl)- groups are optionally replaced with -(C=O)-;

wherein R_Z at each occurrence is independently halogen, -OH, -SH, -CN, -CF₃, -OCF₃, C₁-C₆ alkoxy, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkoxy or -NR₁₀₀R₁₀₁;

where R₁₀₀ and R₁₀₁ are independently H, C₁-C₆ alkyl, phenyl, CO(C₁-C₆ alkyl) or SO₂C₁-C₆ alkyl;

X is -(C=O)-, -(C=S)-, -(SO₂)-;

R₁ is C₁-C₁₀ alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, =O, -SH, -CN, -CF₃, -OCF₃, -C₃₋₇ cycloalkyl, -C₁-C₄ alkoxy, amino, mono-dialkylamino, aryl, heteroaryl, and heterocycloalkyl, wherein each aryl group is optionally substituted with 1, 2 or 3 R₅₀ groups;

R₅₀ is selected from halogen, OH, SH, CN, -CO-(C₁-C₄ alkyl), -NR₇R₈, -S(O)₀₋₂-(C₁-C₄ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₈ alkoxy, -O-benzyl, alkenyloxy, alkoxyalkoxyalkoxy, and C₃-C₈ cycloalkyl;

wherein the alkyl, alkenyl, alkynyl, alkoxy and cycloalkyl groups are optionally substituted with 1 or 2 substituents independently selected from C₁-C₄ alkyl, halogen, OH, -NR₅R₆, CN, C₁-C₄ haloalkoxy, NR₇R₈, and C₁-C₄ alkoxy;

R₅ and R₆ are independently H or C₁-C₆ alkyl; or

R₅ and R₆ and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring; and

R₇ and R₈ are independently selected from H; -C₁-C₄ alkyl optionally substituted with 1, 2, or 3 groups independently selected from -OH, -NH₂, and halogen; -C₃-C₆ cycloalkyl; -(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl); -C₂-C₄ alkenyl; and -C₂-C₄ alkynyl;

wherein each heteroaryl is optionally substituted with 1 or 2 R₅₀ groups;

wherein each heterocycloalkyl group is optionally substituted with 1 or 2 groups that are independently R₅₀ or =O;

R₂ and R₃ are independently selected from

-H;

-F;

-C₁-C₆ alkyl optionally substituted with a substituent selected from -F, -OH, -C≡N, -CF₃, C₁-C₃ alkoxy, and -NR₅R₆;

-(CH₂)₀₋₂-R₁₇;

-(CH₂)₀₋₂-R₁₈;

-C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein each is optionally substituted with an independent substituent selected from -F, -OH, , -C≡N, -CF₃ and C₁-C₃ alkoxy;

-(CH₂)₀₋₂-C₃-C₇ cycloalkyl, optionally substituted an independent substituent selected from -F, -OH, , -C≡N, -CF₃, C₁-C₃ alkoxy and -NR₅R₆; or

wherein R₂, R₃ and the carbon to which they are attached form a carbocycle of three thru seven carbon atoms, wherein one carbon atom is optionally replaced by a group selected from -O-, -S-, -SO₂-, or -NR₇-;

where R₁₇ at each occurrence is an aryl group selected from phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl and tetralinyl, wherein said aryl groups are optionally substituted with one or two groups that are independently -C₁-C₃ alkyl; -C₁-C₄ alkoxy; CF₃; or

-C₂-C₆ alkenyl or -C₂-C₆ alkynyl each of which is optionally substituted with one substituent selected from F, OH, C₁-C₃ alkoxy; or

-halogen;

-OH;

-C≡N;

-C₃-C₇ cycloalkyl;

-CO-(C₁-C₄ alkyl);

-SO₂-(C₁-C₄ alkyl);

where R₁₈ is a heteroaryl group selected from pyridinyl, pyrimidinyl, quinolinyl, indolyl, pyridazinyl, pyrazinyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, furanyl, thienyl, pyrrolyl, oxadiazolyl or thiadiazolyl, wherein each of said heteroaryl groups is optionally substituted with one or two groups that are independently

-C₁-C₆ alkyl optionally substituted with one substituent selected from OH, C≡N, CF₃, C₁-C₃ alkoxy, and -NR₅R₆;

wherein R₁₅ is selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy C₁-C₆ alkyl, hydroxy C₁-C₆ alkyl, halo C₁-C₆ alkyl, benzyl, -C(O)₂-benyl, and alkoxycarbonyl, wherein the alkyl and phenyl portion of each is unsubstituted or substituted with 1, 2, 3, or 4 groups independently selected from halogen, C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy, NH₂, and -R₂₆-R₂₇;

wherein R₂₆ is selected from a bond, -C(O)-, -SO₂-, -CO₂-, -C(O)NR₅-, and -NR₅C(O)-,

wherein R₂₇ is selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, aryl C₁-C₆ alkyl, heterocycloalkyl, and heteroaryl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen, haloalkyl, hydroxyalkyl, -NR₅R₆, -C(O)NR₅R₆;

wherein R_C is selected from

-(CH₂)₀₋₃-(C₃-C₈) cycloalkyl wherein the cycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from -R₂₀₅, and -CO₂-(C₁-C₄ alkyl);

-(CR₂₄₅R₂₅₀)₀₋₄-aryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl;

-(CR₂₄₅R₂₅₀)₀₋₄-aryl-heteroaryl;

-(CR₂₄₅R₂₅₀)₀₋₄-aryl-heterocycloalkyl;

-(CR₂₄₅R₂₅₀)₀₋₄-aryl-aryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-aryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-heterocycloalkyl;

-(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-heteroaryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-heteroaryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-heterocycloalkyl;

$-(\text{CR}_{245}\text{R}_{250})_{0-4}$ -heterocycloalkyl-aryl;

- a monocyclic or bicyclic ring of 5, 6, 7, 8, 9, or 10 carbons fused to 1 or 2 aryl, heteroaryl, or heterocycloalkyl groups wherein 1, 2 or 3 carbons of the monocyclic or bicyclic ring is optionally replaced with

-NH,

$-\text{N}(\text{CO})_{0-1}\text{R}_{215}$,

$-\text{N}(\text{CO})_{0-1}\text{R}_{220}$,

-O, or

$-\text{S}(=\text{O})_{0-2}$,

and wherein the monocyclic or bicyclic ring is optionally substituted with 1, 2 or 3 groups that are independently $-\text{R}_{205}$, $-\text{R}_{245}$, $-\text{R}_{250}$ or $=\text{O}$;

$-\text{C}_2$ - C_6 alkenyl optionally substituted with 1, 2, or 3 R_{205} groups;

$-\text{C}_2$ - C_6 alkynyl optionally substituted with 1, 2, or 3 R_{205} groups;

wherein each aryl group attached directly or indirectly to the $-(\text{CR}_{245}\text{R}_{250})_{0-4}$ group is optionally substituted with 1, 2, 3 or 4 R_{200} groups;

wherein each heteroaryl group attached directly or indirectly to the $-(\text{CR}_{245}\text{R}_{250})_{0-4}$ group is optionally substituted with 1, 2, 3, or 4 R_{200} ;

wherein each heterocycloalkyl attached directly or indirectly to the $-(\text{CR}_{245}\text{R}_{250})_{0-4}$ group is optionally substituted with 1, 2, 3, or 4 R_{210} ;

wherein R_{200} at each occurrence is independently selected from

$-\text{C}_1$ - C_6 alkyl optionally substituted with 1, 2, or 3 R_{205} groups;

-OH;

$-\text{NO}_2$;

-halogen;

$-\text{C}\equiv\text{N}$;

-CHO;

$-(\text{CH}_2)_{0-4}-\text{CO}-\text{NR}_{220}\text{R}_{225}$;

$-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_1-\text{C}_8 \text{ alkyl})$;

$-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_2-\text{C}_8 \text{ alkenyl})$;

$-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_2-\text{C}_8 \text{ alkynyl})$;

$-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_3-\text{C}_7 \text{ cycloalkyl})$;

$-(\text{CH}_2)_{0-4}-(\text{CO})_{0-1}$ -aryl;

$-(\text{CH}_2)_{0-4}-(\text{CO})_{0-1}$ -heteroaryl;

$-(CH_2)_{0-4}-(CO)_{0-1}$ -heterocycloalkyl;
 $-(CH_2)_{0-4}-CO_2R_{215}$;
 $-(CH_2)_{0-4}-SO_2-NR_{220}R_{225}$;
 $-(CH_2)_{0-4}-S(O)_{0-2}-(C_1-C_8 \text{ alkyl})$;
 $-(CH_2)_{0-4}-S(O)_{0-2}-(C_3-C_7 \text{ cycloalkyl})$;
 $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-CO_2R_{215}$;
 $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-SO_2-R_{220}$;
 $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-CO-N(R_{215})_2$;
 $-(CH_2)_{0-4}-N(-H \text{ or } R_{215})-CO-R_{220}$;
 $-(CH_2)_{0-4}-NR_{220}R_{225}$;
 $-(CH_2)_{0-4}-O-CO-(C_1-C_6 \text{ alkyl})$;
 $-(CH_2)_{0-4}-O-(R_{215})$;
 $-(CH_2)_{0-4}-S-(R_{215})$;
 $-(CH_2)_{0-4}-O-(C_1-C_6 \text{ alkyl optionally substituted with 1, 2, 3, or 5 -F})$;
 $-C_2-C_6 \text{ alkenyl optionally substituted with 1 or 2 } R_{205} \text{ groups}$;
 $-C_2-C_6 \text{ alkynyl optionally substituted with 1 or 2 } R_{205} \text{ groups}$;
 and

$-(CH_2)_{0-4}-C_3-C_7 \text{ cycloalkyl}$;

wherein each aryl group included within R_{200} is optionally substituted with 1, 2, or 3 groups that are independently

$-R_{205}$,

$-R_{210}$ or

$-C_1-C_6 \text{ alkyl substituted with 1, 2, or 3 groups that are independently } R_{205} \text{ or } R_{210}$;

wherein each heterocycloalkyl group included within R_{200} is optionally substituted with 1, 2, or 3 groups that are independently R_{210} ;

wherein each heteroaryl group included within R_{200} is optionally substituted with 1, 2, or 3 groups that are independently

$-R_{205}$,

$-R_{210}$, or

$-C_1-C_6 \text{ alkyl substituted with 1, 2, or 3 groups that are independently}$

$-R_{205}$ or

$-R_{210}$;

wherein R_{205} at each occurrence is independently selected from

-C₁-C₆ alkyl,
 -C₂-C₆ alkenyl,
 -C₂-C₆ alkynyl,
 -C₁-C₆ haloalkoxy,
 -(CH₂)₀₋₃(C₃-C₇ cycloalkyl)
 -halogen,
 -(CH₂)₀₋₆-OH,
 -O-phenyl,
 -alkenyl-phenyl,
 -SH,
 -(CH₂)₀₋₆-C≡N,
 -(CH₂)₀₋₆-C(=O)NR₂₃₅R₂₄₀
 -CF₃,
 -C(O)₂-benzyl,
 -C₁-C₆ alkoxy, and
 -NR₂₃₅R₂₄₀,

wherein R₂₁₀ at each occurrence is independently selected from

-C₁-C₆ alkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
 -C₂-C₆ alkenyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
 -C₂-C₆ alkynyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
 -halogen;
 -C₁-C₆ alkoxy;
 -C₁-C₆ haloalkoxy;
 -NR₂₂₀R₂₂₅;
 -OH;
 -C≡N;
 -C₃-C₇ cycloalkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
 -CO-(C₁-C₄ alkyl);
 -SO₂-NR₂₃₅R₂₄₀;
 -CO-NR₂₃₅R₂₄₀;
 -SO₂-(C₁-C₄ alkyl); and
 =O; wherein

wherein R₂₁₅ at each occurrence is independently selected from

-C₁-C₆ alkyl,
-(CH₂)₀₋₂-(aryl),
-C₂-C₆ alkenyl,
-C₂-C₆ alkynyl,
-C₃-C₇ cycloalkyl,
-(CH₂)₀₋₂-(heteroaryl), and
-(CH₂)₀₋₂-(heterocycloalkyl);

wherein the aryl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 groups that are independently

-R₂₀₅ or

-R₂₁₀;

wherein the heterocycloalkyl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 R₂₁₀;

wherein each heteroaryl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 R₂₁₀;

wherein R₂₂₀ and R₂₂₅ at each occurrence are independently selected from

-H,
-C₁-C₆ alkyl,
-hydroxy C₁-C₆ alkyl,
-amino C₁-C₆ alkyl,
-halo C₁-C₆ alkyl,
-(CH₂)₀₋₂-(C₃-C₇ cycloalkyl),
-(C₁-C₆ alkyl)-O-(C₁-C₃ alkyl),
-C₂-C₆ alkenyl,
-C₂-C₆ alkynyl,
-aryl,
-heteroaryl, and
-heterocycloalkyl;

wherein the aryl, heteroaryl or heterocycloalkyl group included within R₂₂₀ and R₂₂₅ is optionally substituted with 1, 2, or 3 R₂₇₀ groups,

wherein R₂₇₀ at each occurrence is independently

-R₂₀₅,

-C₁-C₆ alkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;

- C₂-C₆ alkenyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
- C₂-C₆ alkynyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
- halogen;
- C₁-C₆ alkoxy;
- C₁-C₆ haloalkoxy;
- NR₂₃₅R₂₄₀;
- OH;
- C≡N;
- C₃-C₇ cycloalkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;
- CO-(C₁-C₄ alkyl);
- SO₂-NR₂₃₅R₂₄₀;
- CO-NR₂₃₅R₂₄₀;
- SO₂-(C₁-C₄ alkyl); and
- =O;

wherein R₂₃₅ and R₂₄₀ at each occurrence are independently

- H, or
- C₁-C₆ alkyl;
- phenyl

wherein R₂₄₅ and R₂₅₀ at each occurrence are independently selected from

- H,
- (CH₂)₀₋₄CO₂C₁-C₄ alkyl
- (CH₂)₀₋₄C(=O)C₁-C₄ alkyl
- C₁-C₄ alkyl,
- C₁-C₄ hydroxyalkyl,
- C₁-C₄ alkoxy,
- C₁-C₄ haloalkoxy,
- (CH₂)₀₋₄-C₃-C₇ cycloalkyl,
- C₂-C₆ alkenyl,
- C₂-C₆ alkynyl,
- (CH₂)₀₋₄ aryl,
- (CH₂)₀₋₄ heteroaryl, and
- (CH₂)₀₋₄ heterocycloalkyl, or

wherein R_{245} and R_{250} are taken together with the carbon to which they are attached to form a monocycle or bicycle of 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, optionally where 1 or 2 carbon atoms is replaced by a heteroatom selected from

-O-,

-S-,

-SO₂-, and

-NR₂₂₀-; or wherein a -CH₂- group is replaced with a -C(O)- group;

wherein the aryl, heteroaryl or heterocycloalkyl group included within R_{245} and R_{250} is optionally substituted with 1, 2, or 3 groups that are independently halogen, C₁₋₆ alkyl, CN or OH.

2. (Original) A compound according to claim 1, wherein Z is (C₃-C₇ cycloalkyl)₀₋₁(C₁-C₆ alkyl)-, (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkenyl)-, (C₃-C₇ cycloalkyl)₀₋₁(C₂-C₆ alkynyl)- or (C₃-C₇ cycloalkyl)-, wherein each of said groups is optionally substituted with 1, 2, or 3 R_z groups; wherein, R_z at each occurrence is independently halogen, -OH, -CN, C₁-C₆ alkoxy, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkoxy, -NR₁₀₀R₁₀₁; where R_{100} and R_{101} are independently H, C₁-C₆ alkyl, phenyl, CO(C₁-C₆ alkyl) or SO₂C₁-C₆ alkyl.
3. (Original) A compound according to claim 1, wherein X is -(C=O)-.
4. (Original) A compound according to claim 3, wherein Z is H.
5. (Original) A compound according to claim 1, wherein R_1 is C₁-C₁₀ alkyl optionally substituted with 1 or 2 groups independently selected from halogen, -OH, =O, -CF₃, -OCF₃, -C₃₋₇ cycloalkyl, -C₁-C₄ alkoxy, amino or aryl, wherein the aryl group is optionally substituted with 1 or 2 R_{50} groups; wherein R_{50} is selected from halogen, OH, -CO-(C₁-C₄ alkyl), -NR₇R₈, C₁-C₆ alkyl, C₁-C₆ alkoxy and C₃-C₈ cycloalkyl; wherein the alkyl, alkoxy and cycloalkyl groups are optionally substituted with 1 or 2 substituents independently selected from C₁-C₄ alkyl, halogen, OH, -NR₅R₆, NR₇R₈, and C₁-C₄ alkoxy; wherein R_5 and R_6 are independently H or C₁-C₆ alkyl; or

wherein R₅ and R₆ and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring; and

wherein R₇ and R₈ are independently selected from -H; -C₁-C₄ alkyl optionally substituted with 1, 2, or 3 groups independently selected from -OH, -NH₂, and halogen; -C₃-C₆ cycloalkyl; -(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl).


6. (Original) A compound according to claim 5, wherein R₁ is -CH₂-phenyl where the phenyl ring is optionally substituted with 1 or 2 groups independently selected from halogen, C₁-C₂ alkyl, C₁-C₂ alkoxy and hydroxy.

7. (Original) A compound according to claim 6, wherein R₁ is benzyl, 3-fluorobenzyl or 3,5-difluorobenzyl.

8. (Original) A compound according to claim 1, wherein R₁₅ is H.

9. (Original) A compound according to claim 7, wherein R₁₅ is H.

10. (Original) A compound according to claim 1 of the formula II:



wherein Z is hydrogen, -C₁-C₆ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl or -C₃-C₇ cycloalkyl, where each of said groups is optionally substituted with 1 or 2 R_Z groups, wherein 1 or 2 methylene groups within said -C₁-C₆ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl or -C₃-C₇ cycloalkyl groups are optionally replaced with -(C=O)-;

wherein R_Z at each occurrence is independently halogen, -OH, -CN, -CF₃, C₁-C₆ alkoxy, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkoxy or -NR₁₀₀R₁₀₁;

where R₁₀₀ and R₁₀₁ are independently H, C₁-C₆ alkyl, phenyl, CO(C₁-C₆ alkyl) or SO₂C₁-C₆ alkyl;

wherein X is -C(=O)-;

wherein R₁ is C₁-C₁₀ alkyl optionally substituted with 1 or 2 groups independently selected from halogen, -OH, =O, -CN, -CF₃, -OCF₃, -C₃-C₇ cycloalkyl, -C₁-C₄ alkoxy, amino, mono-

dialkylamino, aryl, heteroaryl or heterocycloalkyl, wherein the aryl group is optionally substituted with 1 or 2 R₅₀ groups;

where R₅₀ is halogen, OH, CN, -CO-(C₁-C₄ alkyl), -NR₇R₈, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy and C₃-C₈ cycloalkyl;

where R₇ and R₈ are selected from H; -C₁-C₄ alkyl optionally substituted with 1, 2, or 3 groups selected from -OH, -NH₂ and halogen; -C₃-C₆ cycloalkyl; -(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl); -C₂-C₄ alkenyl; and -C₂-C₄ alkynyl;

wherein R_C is selected from

-(CR₂₄₅R₂₅₀)₀₋₄-aryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl;

-(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl;

where the aryl group attached to the -(CR₂₄₅R₂₅₀)₀₋₄- group is optionally substituted with 1, 2, 3 or 4 R₂₀₀ groups;

where the heteroaryl group attached to the -(CR₂₄₅R₂₅₀)₀₋₄- group is optionally substituted with 1, 2, 3, or 4 R₂₀₀ groups;

where the heterocycloalkyl group attached to the -(CR₂₄₅R₂₅₀)₀₋₄- group is optionally substituted with 1, 2, 3, or 4 R₂₁₀ groups.

11. (Original) A compound according to claim 10, wherein

Z is -C₁-C₆ alkyl;

R₁ is C₁-C₁₀ alkyl substituted with 1 phenyl group, where the phenyl group attached to the alkyl is optionally substituted with 1 or 2 R₅₀ groups, where each R₅₀ is independently halogen, OH, CN, or C₁-C₆ alkyl; and

R_C is -(CR₂₄₅R₂₅₀)₀₋₄-aryl or -(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl, where the aryl and heteroaryl groups are optionally substituted with 1 or 2 R₂₀₀ groups.

12. (Original) A compound according to claim 1 which is

N-[(1S,2R)-3-[(3-bromobenzyl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4R)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4S)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-[[1-(3-bromophenyl)cyclopropyl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide hydrochloride;

methyl 3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-(3-bromophenyl)propanoate;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl)acetamide;

methyl 3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-(3-ethylphenyl)propanoate;

3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-(3-ethylphenyl)propanoic acid;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)-3-hydroxypropyl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(1S)-1,2,3,4-tetrahydronaphthalen-1-ylamino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl)acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-methylamino-acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl)acetamide;

methyl 3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-(3-iodophenyl)propanoate;

methyl 3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-[3-(3-hydroxyprop-1-ynyl)phenyl]propanoate;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[3-hydroxy-1-(3-iodophenyl)propyl]amino]propyl)acetamide;

methyl 3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-[3-(3-hydroxypropyl)phenyl]propanoate;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)amino]propyl)acetamide;

2-Amino-N-[1-(3,5-difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[6-ethyl-2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-4-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(1S)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(1R)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-[[1-(3-bromophenyl)cyclopropyl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

methyl 3-[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-[3-(5-formylthien-2-yl)phenyl]propanoate;

methyl 3-[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-(2'-acetyl-1,1'-biphenyl-3-yl)propanoate;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-methyl-butylamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({1-[3'-(hydroxymethyl)-1,1'-biphenyl-3-yl]cyclopropyl}amino)propyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({1-[3-(5-formylthien-2-yl)phenyl]cyclopropyl}amino)-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-(9H-fluoren-9-ylamino)-2-hydroxypropyl]acetamide;

methyl 3-[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-[3-(trifluoromethyl)phenyl]propanoate;

methyl 3-[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-(3-cyanophenyl)propanoate;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-hydroxy-2,2-dimethyl-propionamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)cyclopropyl]amino]-2-hydroxypropyl)acetamide;

methyl 3-[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-(3-bromophenyl)propanoate;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethynylphenyl)cyclopropyl]amino]-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-[(2-bromo-9H-fluoren-9-yl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-ethyl-9H-fluoren-9-yl)amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-iodo-3,4-dihydro-2H-chromen-4-yl)amino]propyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4S)-6-iodo-3,4-dihydro-2H-chromen-4-yl]amino]propyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4R)-6-iodo-3,4-dihydro-2H-chromen-4-yl]amino]propyl]acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-hydroxy-propionamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[4-(3-ethylphenyl)tetrahydro-2H-pyran-4-yl]amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)butyl]amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[4S)-6-ethyl-3,4-dihydro-2H-chromen-4-yl]amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[4R)-6-ethyl-3,4-dihydro-2H-chromen-4-yl]amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[(7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)amino]-2-hydroxypropyl]acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-hydroxy-butyramide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)cyclohexyl]amino]-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)cyclopentyl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-ethyl-5-fluoro-9H-fluoren-9-yl)amino]-2-hydroxypropyl)acetamide;

methyl (3S)-3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-(3-ethylphenyl)butanoate;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3-isobutylisoxazol-5-yl)cyclopropyl]amino]propyl)acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-phenyl-acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-ethyl-7-fluoro-9H-fluoren-9-yl)amino]-2-hydroxypropyl)acetamide;

methyl (3R)-3-[[[(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino]-3-(3-ethylphenyl)butanoate;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,5-dipropylbenzyl)amino]-2-hydroxypropyl)acetamide;

{[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propylcarbamoyl]-methyl}-methyl-carbamic acid tert-butyl ester;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(2-isobutyl-9H-fluoren-9-yl)amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethyl-2,3-dihydro-1H-inden-1-yl)amino]-2-hydroxypropyl)acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-methyl-2-methylamino-propionamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-ethyl-1-(3-ethylphenyl)propyl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-2,1-benzothiazin-4-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-2,1-benzothiazin-4-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-1-methyl-1,2,3,4-tetrahydroquinolin-4-yl)amino]-2-hydroxypropyl)acetamide;

methyl 3-([(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-(3-ethylphenyl)propanoate;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-(1H-imidazol-4-yl)-acetamide;

methyl 3-([(2R,3S)-3-(acetylamino)-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino)-3-(3-ethylphenyl)propanoate;

N-[(1S,2R)-3-[(2-bromo-9-methyl-9H-fluoren-9-yl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[2-(1-ethylpropyl)-9H-fluoren-9-yl]amino]-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-[(2-cyclopentyl-9H-fluoren-9-yl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2⁶-isothiochroman-4-ylamino)-2-hydroxy-propyl]-propionamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-ethyl-9-methyl-9H-fluoren-9-yl)amino]-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-[(2-cyclohexyl-9H-fluoren-9-yl)amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(4-ethylpyridin-2-yl)cyclopropyl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(4S)-6-(1H-pyrrol-3-yl)-3,4-dihydro-2H-chromen-4-yl]amino)propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[5R)-3-ethyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl]amino]-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-[[1-(3-bromophenyl)-1-methylethyl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[2-(dimethylamino)-9H-fluoren-9-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3,4-tetrahydronaphthalen-1-yl)amino]propyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[(1S)-7-[(dimethylamino)methyl]-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl]acetamide;

N-[(1S,2R)-3-[(1S)-7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3-propylphenyl)cyclopropyl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)cycloheptyl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-isopropyl-3,4-dihydro-2H-chromen-4-yl)amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[(2-ethyl-6-fluoro-9H-fluoren-9-yl)amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[2-(methoxymethyl)-9H-fluoren-9-yl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)-2-(5-methyl-1,3-oxazol-2-yl)ethyl]amino]-2-hydroxypropyl)acetamide hydrochloride;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-(3,4-dihydro-2H-chromen-4-ylamino)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[2-ethyl-5-(trifluoromethyl)-9H-fluoren-9-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[2-(3-methylbutyl)-9H-fluoren-9-yl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[2-isopropyl-9H-fluoren-9-yl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[2-neopentyl-9H-fluoren-9-yl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(2-isopropenyl-9H-fluoren-9-yl)amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(3-ethylphenyl)-1-methylethyl]amino]-2-hydroxypropyl)acetamide hydrochloride;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[[(4S)-6-isobutyl-3,4-dihydro-2H-chromen-4-yl]amino]propyl]acetamide;

N-((1S,2R)-3-[[[(4S)-6-cyano-3,4-dihydro-2H-chromen-4-yl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino]propyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-neopentyl-3,4-dihydro-2H-chromen-4-yl)amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[2-(isopropylamino)-9H-fluoren-9-yl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3-isobutylphenyl)cyclopropyl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[[(4-isobutyl-1,1'-biphenyl-2-yl)methyl]amino]propyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[7-(2,2-dimethylpropyl)-5-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[[(4R)-6-(2,2-dimethylpropyl)-3,4-dihydro-2H-chromen-4-yl]amino]-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[[(1S)-7-(2,2-dimethylpropyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-2-hydroxypropyl]acetamide;

N-[(1S,2R)-3-[[1-(3-tert-butylphenyl)cyclohexyl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-[(1S,2R)-3-[[4-(3-tert-butylphenyl)tetrahydro-2H-pyran-4-yl]amino]-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[6-(2,2-dimethylpropyl)-1,2,3,4-tetrahydroquinolin-4-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3-isopropylphenyl)-4-oxocyclohexyl]amino]propyl)acetamide;

N-[(1S,2R)-3-[[[(4S)-6-(2,2-dimethylpropyl)-3,4-dihydro-2H-chromen-4-yl]amino]-1-(3-

fluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[5-(2,2-dimethylpropyl)-2-(1H-imidazol-1-yl)benzyl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[7-(2,2-dimethylpropyl)-1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[6-(2,2-dimethylpropyl)-4-methyl-3,4-dihydro-2H-chromen-4-yl]amino]-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3-fluoro-4-hydroxybenzyl)-2-hydroxy-3-[[1-(3-isopropylphenyl)cyclohexyl]amino]propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3-isopropylphenyl)cyclohexyl]amino]propyl)-2-fluoroacetamide;

N-((1S,2R)-1-[3-(allyloxy)-5-fluorobenzyl]-2-hydroxy-3-[[1-(3-isopropylphenyl)cyclohexyl]amino]propyl)acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-[3-(2,2-dimethylpropyl)phenyl]-1-methylethyl]amino]-2-hydroxypropyl]-2-fluoroacetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(1S)-7-(2,2-dimethylpropyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-2-hydroxypropyl)-2-fluoroacetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-[3-(3-thienyl)phenyl]cyclohexyl]amino]propyl]acetamide;

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-[4-(2,2-dimethylpropyl)pyridin-2-yl]cyclopropyl]amino]-2-hydroxypropyl]acetamide;

N-((1R,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(1S)-7-propyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propyl)acetamide;


N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[[1-(3-isobutylphenyl)cyclohexyl]amino]propyl)acetamide;

N-((1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-[[1-(3-isopropylphenyl)cyclohexyl]amino]propyl)acetamide;

N-((1R,2S)-1-(3,5-difluorobenzyl)-3-[[1-(1S)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-2-hydroxypropyl)-2-ethoxyacetamide; or


N-((1S,2R)-1-(3,5-difluorobenzyl)-3-[[1-(1R)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-2-hydroxypropyl)-2,2-difluoroacetamide; or a pharmaceutically acceptable salt thereof.

13. (Currently Amended) A method for preparing a compound or salt of the formula




or a pharmaceutically acceptable salt thereof, of claim 1, wherein Z, X, R₁, R₂, R₃, R₁₅ and R_c are as defined in claim 1, said method comprising


a) reacting an epoxide of the formula




where PG is a nitrogen protecting group that is Cbz, Boc, or benzyl, with a compound of formula H(R₁₅)N-R_c, to form a compound of the formula:



b) deprotecting the amine to form a compound of the formula:



c) coupling the deprotected amine with a compound of formula Z-X-LG, where LG is a leaving group, to form a compound of the formula:



14. (Currently Amended) ~~The use of a compound or salt according to claim 1 for the manufacture of a medicament for use in:~~ A method of treating a subject who has, ~~or in preventing a subject from developing~~ Alzheimer's disease (AD); ~~preventing or delaying the onset of Alzheimer's disease;~~ treating subjects with mild cognitive impairment (MCI); ~~preventing or delaying the onset of Alzheimer's disease in subjects who would progress from MCI to AD;~~ treating Down's syndrome; treating subjects who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type; treating cerebral amyloid angiopathy and preventing its potential

consequences; treating other degenerative dementias; treating dementia associated with Parkinson's disease, progressive supranuclear palsy, or cortical basal degeneration; treating diffuse Lewy body type AD; and ~~treating~~ frontotemporal dementias with parkinsonism (FTDP), the method comprising administering a therapeutically effective amount of a compound or salt of claim 1 to a person in need of such treatment.